Entry |
|
Name |
Olanzapine (JAN/USP/INN); Zyprexa (TN) |
Product |
|
Generic |
OLANZAPINE (American Health Packaging), OLANZAPINE (American Health Packaging), OLANZAPINE (American Regent), OLANZAPINE (Aphena Pharma Solutions - Tennessee), OLANZAPINE (Apotex Corp.), OLANZAPINE (Apotex Corp.), OLANZAPINE (Ascend Laboratories), OLANZAPINE (Aurobindo Pharma Limited), OLANZAPINE (Aurobindo Pharma Limited), OLANZAPINE (AvPAK), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Bryant Ranch Prepack), OLANZAPINE (Cadila Pharmaceuticals Limited), OLANZAPINE (Camber Pharmaceuticals), OLANZAPINE (Cardinal Health 107), OLANZAPINE (Cardinal Health 107), OLANZAPINE (Coupler LLC), OLANZAPINE (Direct_Rx), OLANZAPINE (Dr. Reddy's Laboratories), OLANZAPINE (Dr. Reddy's Laboratories), OLANZAPINE (Dr. Reddy's Laboratories), OLANZAPINE (Dr.Reddy's Laboratories Limited), OLANZAPINE (Eugia US LLC), OLANZAPINE (Golden State Medical Supply), OLANZAPINE (Golden State Medical Supply), OLANZAPINE (Hisun Pharmaceuticals USA), OLANZAPINE (Indoco Remedies Limited), OLANZAPINE (Jubilant Cadista Pharmacuticals), OLANZAPINE (Lannett Company), OLANZAPINE (Macleods Pharmaceuticals Limited), OLANZAPINE (Macleods Pharmaceuticals Limited), OLANZAPINE (Major Pharmaceuticals), OLANZAPINE (Major Pharmaceuticals), OLANZAPINE (Major Pharmaceuticals), OLANZAPINE (Modavar Pharmaceuticals LLC), OLANZAPINE (Mylan Pharmaceuticals), OLANZAPINE (NCS HealthCare of KY), OLANZAPINE (NorthStar RxLLC), OLANZAPINE (NorthStar RxLLC), OLANZAPINE (PD-Rx Pharmaceuticals), OLANZAPINE (PD-Rx Pharmaceuticals), OLANZAPINE (Preferred Pharmaceuticals), OLANZAPINE (Preferred Pharmaceuticals), OLANZAPINE (Preferred Pharmaceuticals), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Proficient Rx LP), OLANZAPINE (Qilu Pharmaceutical), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (REMEDYREPACK), OLANZAPINE (RedPharm Drug), OLANZAPINE (RedPharm Drug), OLANZAPINE (Sandoz), OLANZAPINE (Sandoz), OLANZAPINE (Strides Pharma Science Limited), OLANZAPINE (Teva Pharmaceuticals USA), OLANZAPINE (Torrent Pharmaceuticals Limited), OLANZAPINE (Upsher-Smith Laboratories), OLANZAPINE (Zydus Lifesciences Limited), OLANZAPINE (Zydus Lifesciences Limited), OLANZAPINE (Zydus Pharmaceuticals USA) |
Formula |
C17H20N4S
|
Exact mass |
312.1409
|
Mol weight |
312.43
|
Structure |

|
Simcomp |
|
Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01644 CYP2D6 substrate
|
Remark |
Product (DG00898): | D00454<JP/US> D06623<US> |
Product (mixture): | D10206<US> D12117<US> |
|
Efficacy |
Antipsychotic |
Disease |
Schizophrenia [DS: H01649] Bipolar I disorder, manic or mixed episodes [DS: H01653] |
Comment |
Multi-acting-receptor-targeting-antipsychotics (MARTA)
|
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
|
Metabolism |
Enzyme: CYP1A2 [HSA: 1544]; CYP2D6 [HSA: 1565]
|
Interaction |
|
Structure map |
map07211 | Serotonin receptor agonists/antagonists |
map07213 | Dopamine receptor agonists/antagonists |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH03 Olanzapine
D00454 Olanzapine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antipsychotics
2nd Generation/Atypical
Olanzapine
D00454 Olanzapine (JAN/USP/INN)
Bipolar Agents
Bipolar Agents, Other
Olanzapine
D00454 Olanzapine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D00454 Olanzapine (JAN/USP/INN)
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2391 Antiemetics
D00454 Olanzapine (JAN/USP/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00898 Olanzapine
D00454 Olanzapine
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG00898 Olanzapine
D00454 Olanzapine
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00898 Olanzapine
D00454 Olanzapine
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00898 Olanzapine
D00454 Olanzapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00898 Olanzapine
D00454 Olanzapine
DG01644 CYP2D6 substrate
DG00898 Olanzapine
D00454 Olanzapine
Drug classes [BR:br08332]
Anti-allergic agent
DG01482 Histamine receptor H1 antagonist
D00454 Olanzapine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D00454 Olanzapine (JAN/USP/INN) <JP/US>
Dopamine
DRD2
D00454 Olanzapine (JAN/USP/INN) <JP/US>
DRD3
D00454 Olanzapine (JAN/USP/INN) <JP/US>
DRD4
D00454 Olanzapine (JAN/USP/INN) <JP/US>
Histamine
HRH1
D00454 Olanzapine (JAN/USP/INN) <JP/US>
Serotonin
HTR2
D00454 Olanzapine (JAN/USP/INN) <JP/US>
HTR6
D00454 Olanzapine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00454
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00454
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00454
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00898 Olanzapine
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG00898 Olanzapine
DG03200 Antipsychotic agent
DG03064 Atypical antipsychotic
DG00898 Olanzapine
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG00898 Olanzapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00898 Olanzapine
DG01644 CYP2D6 substrate
DG00898 Olanzapine
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 22
1 C8y C 18.4919 -10.5513
2 C8y C 17.6483 -9.4316
3 C8y C 17.9905 -8.0673
4 N4x N 19.2617 -7.4901
5 N5x N 19.9065 -10.5817
6 C8y C 20.5211 -8.1208
7 C8y C 20.8046 -9.4994
8 S2x S 16.7987 -7.3203
9 C8y C 15.7200 -8.2230
10 C8x C 16.2450 -9.4575
11 C1a C 14.3803 -7.9003
12 N1y N 17.7660 -11.7484
13 C8x C 22.1331 -9.9409
14 C8x C 23.1798 -9.0111
15 C8x C 22.8963 -7.6326
16 C8x C 21.5678 -7.1910
17 C1x C 16.3806 -11.7887
18 C1x C 15.7162 -13.0210
19 N1y N 16.4511 -14.2126
20 C1x C 17.8365 -14.2422
21 C1x C 18.5010 -12.9400
22 C1a C 15.7566 -15.4262
BOND 25
1 3 4 1
2 1 5 2
3 4 6 1
4 2 3 2
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 1
9 8 9 1
10 9 10 2
11 2 10 1
12 9 11 1
13 1 12 1
14 7 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 6 16 2
19 12 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 12 21 1
25 19 22 1
|
|